Stock Analiz

Citius Pharmaceuticals, Inc. CTXR

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.54Market cap $15M
Open the interactive analysis →

Citius Pharmaceuticals, Inc. (CTXR) is a healthcare company listed in the US with a market value of about $15M.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.

About Citius Pharmaceuticals

Citius Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $50000 in 2017 to $90000 in 2022, growth of about 12.5% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 89% over three years (dilution for shareholders).

Score: 0.2 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−100%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-31497.3%
ROIC (5-yr avg.)-25.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue———$90000$90000$90000$90000$75000$50000—
Net income-$37M-$40M-$33M-$34M-$23M-$18M-$16M-$13M-$10M-$8M
Free cash flow————-$24M-$17M——-$8M—
EPS (diluted)$-3.38$-5.97$-5.57$-5.75$-5.75$-11.25$-19.25$-29.25$-47.25$-57.25
Net margin———-37378.5%-25616.0%-19497.9%-17291.3%-16715.5%-20769.9%—
ROIC-8.3%-47.2%-31.8%-25.4%-14.0%-40.0%-43.3%-35.4%-35.7%-33.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Citius Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Citius Pharmaceuticals pay a dividend?

Not currently.

Is Citius Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Citius Pharmaceuticals scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.